hotspot -WSS

hotspot

author：leisure time 2025-08-12 08:25:11 - browse：4

Adam's take main illustration — Molly Ferguson/STAT

Hello! Some takes and thoughts on Gilead’s Trodelvy troubles, Elevation Oncology’s surprising rise, and Kura Oncology’s “wall-crossing” stock sale.

Gilead needs Arcellx more than ever

The clinical trial setback for Trodelvy in non-small cell lung cancer reported by Gilead Sciences on Monday was another dose of bad news for the company’s oncology business. Strategically, does it make sense for Gilead to invest even more in antibody-drug conjugates like Trodelvy, where its lackluster profile and increased competition overall makes winning seem unlikely? Or, should Gilead double down on its Kite division and CAR-T cell therapy — the type of cancer treatments where it truly excels?

If the answers to those questions are no and yes (I lean that way), then Gilead’s current partnership with Arcellx, which is developing a BCMA-targeted CAR-T therapy for multiple myeloma, becomes a lot more important.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Weight loss drugs should be covered by insurers, AMA says

WSS

Cytokinetics CEO stresses company can launch heart drug on its own

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

Wearables generate powerful data but its not useful to doctors, yet

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

Ohio still needs to do more to protect the right to abortion

knowledge

hotspot

Gilead needs Arcellx more than ever

entertainment

State Dept. review finds Biden bears some blame for Afghanistan failures

Helping hospitals and community health centers plan for resilience

Dobbs anniversary: the lost opportunity of abortion as health care

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

At least 13 dead in Texas as scorching temps continue

Solving academic medical centers' existential crisis

Continuity nursing helped my family in our darkest PICU moments

Type 2 diabetes prevention programs work at large scale: study

Jerome Adams on the need for new antivirals for Covid

Readout Newsletter: Zepbound, Valneva's vaccine, and more

knowledge

Solving academic medical centers' existential crisis

Glen Campbell's doctor discusses his public struggle with Alzheimer's

UnitedHealth sued over use of algorithm in Medicare Advantage plans

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

hotspot

explore

hotspot

hotspot